Collaboration and License Agreements - Contract Liabilities - Additional Information (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Deferred revenue | $ 28,467 | $ 94,063 | $ 212,315 |
| Astellas Pharma Inc. | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Deferred revenue | $ 8,600 | ||
| Deferred Revenue Recognition Maturity Year | 2026 | ||
| ModernaTX, Inc | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Deferred revenue | $ 9,300 | ||
| Regeneron Pharmaceuticals, Inc | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Deferred revenue | $ 10,500 | ||
| Deferred Revenue Recognition Maturity Year | 2026 |